Ossur hf
CSE:OSSR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
26.4
34.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Earnings Call Analysis
Q3-2024 Analysis
Ossur hf
Embla Medical delivered solid results for Q3 2024, showcasing a 7% organic sales growth and an impressive 11% growth in local currency. This momentum was particularly evident in the EMEA region, supported by the Prosthetics & Neuro Orthotics and Patient Care segments. Notably, the company maintained a robust EBITDA margin of 22%, bolstered by strategic cost reductions and an improved product mix, reflecting effective management amid market challenges.
The company is executing its Growth '27 strategy effectively, with the introduction of new bionic knee solutions—NAVii and Icon—set to expand further in early 2025. Additionally, Embla Medical launched the third generation of Naked Prosthetics, emphasizing adaptability and enhancements based on user feedback. The acquisition of Fior & Gentz has also strengthened their neuro orthotics portfolio, facilitating access to new markets like the UK and Australia, contributing to their broader goal of supporting individuals with mobility challenges.
Embla Medical reaffirmed its 2024 guidance, projecting organic sales growth of 6% to 8% and an EBITDA margin around 20%, not factoring in significant impacts from recently launched innovations or the U.S. Medicare reforms. These expectations highlight a cautious optimism, particularly as the integration of new products continues and as the potential impact of the expanded Medicare coverage for K2 amputees becomes clearer in the coming quarters.
The geographical breakdown shows strong performance in EMEA, which experienced a notable 13% growth driven by the Prosthetics & Neuro Orthotics segment and patient care services. In contrast, the Americas showed softer sales, impacted by specific challenges in certain categories. APAC demonstrated resilience, particularly in Australia, where the easing reimbursement backlog began to positively influence sales, pointing to a recovering trend.
The Bracing & Supports segment posted modest growth of just 1%, influenced by market dynamics. This part of the business has faced a mixed environment, with strong performance in osteoarthritis solutions contrasting against price pressures in lower-end product categories. However, the overall segment remains strategically important, and the company is committed to maintaining growth amidst competitive market conditions.
Financially, Embla Medical reported a gross profit margin increase to 63%, compared to 62% year-over-year, driven by cost management and efficiency improvements. Operating expenses were effectively managed, growing only 4% organically, which is favorable in comparison to sales growth. The net profit surged 58% to $22 million, demonstrating strong operational leverage. The company’s CapEx has stabilized to 4% of sales, with expectations to normalize going forward.
Embla Medical is navigating complex market dynamics and regulatory changes, particularly in the U.S. with the recent expansion of Medicare coverage for K2 amputees. This change represents a significant opportunity but is expected to yield gradual growth as the market adapts. The company anticipates that the overall share of Medicare in their revenue will remain substantial given that it currently accounts for roughly 30% of revenue in O&P patient care facilities.
Looking ahead, Embla Medical's management is focused on leveraging their enhanced product offerings and navigating evolving markets. The gradual expansion of the ForMotion brand to unify patient care facilities aims to enhance brand recognition and operational synergies. The strategic positioning in neuro orthotics through acquisitions and innovation reflects Embla's commitment to maintaining a strong market presence and addressing the needs of individuals with mobility challenges.
You don't have any saved screeners yet
Good day, and thank you for standing by. Welcome to the Embla Medical Q3 2024 Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Sveinn Solvason, President and CEO. Please go ahead.
Thank you very much, operator, and good morning, and welcome to the Embla Medical conference call, where we will review the third quarter results for 2024. I'm Sveinn Solvason, President and CEO of Embla Medical. And joining me today here from Copenhagen is our Chief Financial Officer, Arna Sveinsdottir; and Embla Medical's Head of Investor Relations, Klaus Sindahl.
Today, we'll discuss the financial performance and progress we've made during the third quarter. The presentation should take roughly 15 minutes, after which there will be an opportunity to ask questions during a Q&A session.
If you go to the next slide, please. We continue to deliver solid growth. Organic sales growth was 7%, and local currency growth was 11%, including an impact from M&A and currency. We continue to see a strong momentum in EMEA, driven by Prosthetics & Neuro Orthotics as well as Patient Care. Our Bracing & Supports business, however, delivered a more modest growth for the quarter. Our EBITDA margin came in strong at 22%, supported by the cost reduction initiatives implemented in our manufacturing operations during the first quarter as well as positive product mix and cost control. Arna will go through our financials in more detail later.
We are executing well on our Growth '27 strategy and reiterate our full year guidance of 6% to 8% organic sales growth and around 20% EBITDA margin before special items. We continue to execute on our strategic initiatives. And in the second quarter, we launched 2 new bionic knee solutions, NAVii by Össur and Icon by College Park. Both solutions continue to be rolled out in selected markets during the year and the full launch of both knee solutions is expected early 2025.
I'm also encouraged to see the third generation of our Naked Prosthetics technology being launched during the third quarter. This generation features some significant enhancements to the finger and hand portfolio with improved durability and personalization. These upgrades were driven by customer feedback and demonstrate how quickly we're able to adapt to feedback from our markets and individuals that use our products.
Nine months ago, we acquired Fior & Gentz, a leading maker of lower limb neuro orthotic components. The acquisition was an important step in our growth journey and an expansion into the field of neuro orthotics, a field we are optimistic about as we are broadening our ability to support individuals with chronic mobility challenges. We are very pleased to see the integration of Fior & Gentz going well. In the third quarter, the Neuro Orthotics portfolio was rolled out in new markets such as the U.K. and Australia. And it's our plan to continue to leverage our commercial infrastructure in other markets to bring neuro orthotic products to even more patients.
As announced in July, it's our intent to unite our network of Patient Care facilities under a new brand identity called ForMotion. The ForMotion brand will be introduced gradually to the markets we operate in within Patient Care. And here during the third quarter, we rebranded our clinics in the Netherlands to ForMotion and additional markets will follow in quarter 4. And ultimately, it's a goal that the ForMotion brand will encompass the entire network of our global O&P patient care facilities as we move forward.
In the U.S., Medicare has expanded access to advanced bionics for less mobile patients, so-called K2 patients. And the coverage expansion took effect 1st of September, and we'll go through some of the important key takeaways from the U.S. Medicare expansion in the coming slides as we've received a lot of questions about this change.
And then last but not least, the global team of our elite para-athletes who wear Össur prosthetics won 22 medals and set 5 new Paralympic records during the 2024 Paralympic Games in Paris, and it was great to see the fantastic performance from our team Össur athletes, who dominated several categories while wearing our carbon fiber Cheetah sport blades.
And if you turn to the next slide, please, on the U.S. Medicare expansion. As earlier mentioned, as of September 1st, U.S. Medicare has expanded its coverage of microprocessor knees, in other words, bionic knees to include K2 amputees. This is the most significant coverage expansion in lower extremity prosthetics we've seen over the last 25 years. For the first time, U.S. Medicare will now allow for less mobile patients with amputations above the knee to receive bionic knees.
Substantial research has, over the years, supported that more advanced prosthetic devices such as bionics lead to significant clinical benefits for less mobile patients, including reduced risk of falling, improved mobility, and increased patient confidence while walking. In turn, health care costs or the cost burden should also decrease over time, while quality of life should substantially increase. In addition, the extended coverage may also grant these functional level K2 amputees access to a compatible high active foot solution as a complement to the bionic knee when certain coverage criteria are met.
And if you turn to the next slide, please. With Medicare's expansion of MPKs to less mobile K2 patients, we see a potential to grow over time as the number of patients that use advanced bionic solutions will increase. These functional level K2 amputees are typically patients characterized by being a limited community walker who can handle curb, stairs and uneven surfaces. Opposite, you have the K3 and K4 patients who today qualify for advanced prosthetic devices. These patients are often characterized by being more active beyond basic needs and can navigate most barriers unhindered. It's still too early for us to quantify the potential uptake and impact on, let's say, the market size as the new policy will not automatically create access for every person currently classified as a K2 amputee.
Today, Medicare accounts for roughly 30% of the revenue of an average O&P patient care facility in the U.S. with an annual coverage of bionic knees of roughly $100 million. While Medicare's coverage expansion does not, as we previously talked about, does not automatically require other payers to follow suit. Historically, this has still been the case with many of the commercial payers that have adopted Medicare's guidelines on coding and fees as a baseline for how they decide on coverage. From a claims perspective, we also know that the number of claims between the K3 and K2 patient populations is roughly the same today. However, in dollar value, the split is more like 90-10 since the more advanced prosthetic solutions have been restricted to the more active K3 or K4 functional level amputees.
If you then turn back to the quarter and go through the geographical overview of our performance. And if you go to the next slide, please, we continue to see strong momentum in EMEA with 13% growth in the quarter. Growth in EMEA was driven by our Prosthetics & Neuro-Orthotics as well as our Patient Care segment. This is the fourth consecutive quarter we have posted double-digit growth in the region. Sales in APAC were solid for the quarter with 6% organic growth, mainly driven by our business in Australia, where we are starting to see an improvement in the reimbursement approvals, which had impacted sales in the first half of the year. Sales in Americas were soft in the quarter, although selected patient care markets in key product categories in Prosthetics & Neuro Orthotics demonstrated good growth, while we had soft sales in other categories and locations. As expected, we are yet to see any impact from U.S. Medicare expanded coverage for K2 patients.
If you turn to the next slide, please. On our Prosthetics & Neuro Orthotics segment, we delivered 9% organic growth for the quarter, driven by strong volume growth and increased fitting of high-end solutions. In EMEA, we saw continued strong momentum driven by, again, volume growth across all our major markets and especially in bionics. In the Americas, sales remained somewhat soft, while sales in APAC were particularly strong in Australia, where we are seeing the reimbursement backlog impacting sales in the first half of the year starting to gradually move back to normal. In the Neuro Orthotics, we continue to see solid performance from Fior & Gentz, which we acquired earlier this year.
And if you turn to the next slide, please, on Bracing & Supports. This segment grew by 1% organically. Growth in this part of our business has, during the year, been impacted by somewhat challenging market dynamics in selected product categories, which has led to soft performance in both EMEA and Americas. In APAC, we continue to deliver a strong quarter, mainly driven by our business in China as well as Australia and New Zealand delivered excellent growth in the region.
And if you turn to the next slide, please, on Patient Care, our Patient Care business delivered strong organic growth in the quarter of 9%, driven by strong patient volume growth and positive mix impact also, especially in Europe and Australia.
Yes, this now concludes our sales performance overview for the quarter, and I would like to hand it over to Arna to go through the financials, please.
Thank you, Sveinn. If you please turn to the next slide for an overview of our financials. Gross profit margin was 63% in the third quarter compared to 62% in the same period last year. The increase is attributed to the cost reduction initiatives in manufacturing executed during the first quarter of the year as well as positive product mix and increased manufacturing efficiency.
We are pleased to see that OpEx growth continued to be well managed. In the third quarter, OpEx grew 4% organic relative to delivering organic sales growth of 7%. With an increase in gross profit margin and effective cost control in our OpEx, I'm pleased to report a strong EBITDA margin for the quarter of 22%, with a 3 percentage point expansion from the same period last year. Net profit grew 58% in the quarter and was $22 million or 10% of sales compared to $14 million or 7% of sales in the third quarter last year. Effective tax rate for the quarter was around 22%.
If you can please turn to the next slide for the status on our cash flow and leverage. During the third quarter, CapEx was $9 million or 4% of sales. CapEx has come down in quarter 3 relative to quarters in the first half of the year as facility expansion programs to support our growth have largely been concluded. All things equal, CapEx is expected to return to more normalized level of 3% to 4% of sales in the coming periods. In third quarter, we delivered strong free cash flow, driven by solid cash generation from our operations. Additionally, positive effects from working capital and lower CapEx contributed to stronger cash flow. Inventories, however, remained somewhat elevated due to buildup of bionic solutions inventory as we are preparing for a full launch early next year. On the leverage, we see our net interest-bearing debt-to-EBITDA ratio coming down, putting us back within our targeted range of 2x to 3x EBITDA. Our share buyback program remains paused, and we will continue to reevaluate the situation as leverage ratio continues to come down.
With this overview, I will hand back to Sveinn for his final remarks and comments around guidance.
Thank you, Arna. Please turn to the next slide. In line with the strong performance we've seen to date, we reiterate our guidance for the full year at 6% to 8% organic sales growth and around 20% EBITDA margin before special items. The guidance does not assume any meaningful impact from the recently launched innovation, including the new bionic knee solutions, as these continue to be rolled out gradually in selected markets as part of our limited launch program. A full launch of NAVii and Icon is expected early '25 as previously announced. Neither do we assume any meaningful impact for 2024 from the U.S. Medicare reform for extended coverage for K2 patients.
With this overview, our presentation is now concluded, and we would like to open the call for questions. Operator, if you can please move to the next slide and the Q&A can begin, please. Thank you.
[Operator Instructions] First question is coming from the line of Natalya Davies from Intron Health.
Just a couple from me. The first is, could we get a sense of the growth rate that you've seen for the Fior & Gentz business and if it's in line with pre-acquisition double-digit growth? And the second question, could you just provide some insights into how your R&D and SG&A costs are projected to evolve through 2025 and 2026, particularly in light of any planned product launches or the rollout of NAVii and Icon's MPK?
Thanks for your questions. On the Fior & Gentz piece, we don't really report specifically on Fior & Gentz, but what we did communicate when we acquired this business is that our expectation is to deliver strong double-digit growth, and that's what we continue to see, also as we start to introduce these products in other markets where we are leveraging our commercial infrastructure globally and relationships with O&P providers.
With regards to sales and marketing and R&D cost, let's say, as you model that going forward, I mean, if we take a step back on the sales and marketing cost, we do have scalability and are well invested in the biggest health care markets, and that scalability has largely been reinvested, you could say, in building our footprint in private pay market. So you should expect some operating leverage, but not much on either sales and marketing nor the R&D line. There's no expected step-up in R&D as such as a percentage of sales, but I would just maybe mention that we do expect R&D cost to be a little bit higher here in quarter 4 on a run rate basis than in quarter 3. I hope that's helpful.
[Operator Instructions] There are no further questions on the telephone. At this time, I would like to hand over for any webcast questions.
Yes. So we received a few questions from Nordea, who has some challenges in dialing in. So the first question is, what is the initial feedback on new product launches, especially the NAVii and the Icon Bionic Knees, which are in limited launch?
Yes, we'll start with that one. We've received good feedback on both products. The NAVii is, you could say, a next generation of a rheologic platform that has some enhanced features, waterproof being one, and some improved stance controls and further improvements, enabling patients to walk up and downstairs. So we are just very encouraged by the feedback we see or we hear on the NAVii and are excited to go into a more full launch mode here in 2025.
There's also questions from Carnegie, but they also have challenges in dialing in. I don't know what...
We will now take the question from Carnegie. Niels Granholm-Leth, your line is open now.
Firstly, can you talk about if you have incurred any extraordinary costs in this quarter related to the rebranding of your ForMotion clinic network. And secondly, could you just extrapolate a little bit on why you don't expect any effect from the broader coverage of bionic products in the U.S. in quarter 4?
Yes. Thanks for your questions. Well, yes, there is cost, obviously, in and around an effort to rebrand our patient care network. We will reinvest part of these, you could call it, sort of the year-over-year marketing cost that we do have in our Patient Care business into this effort. So we will not book any extraordinary cost in this regard and don't expect this to have any, let's say, meaningful impact on our overall financial picture. We will do this gradually over the next couple of years, this moving into the ForMotion brand.
With regards to the ICD changes in the U.S., we are seeing a lot of activity in the market in the sense that our customers are building up knowledge and building their processes in terms of how to fit K2 patients with bionic knees, meaning there is some documentation and some tests required to make sure that reimbursement is there. So we don't -- let's say, we do obviously expect some K2 patients to be fitted with bionics here in quarter 4, but we don't expect this to have any meaningful impact on our growth here in 2024.
Great. Perhaps you could just tell us then, when it comes to the rebranding of your ForMotion network, how long have you come? Are you kind of 20% or 40% into the rebranding process? And then could you also talk about how many countries that you have introduced the Fior & Gentz products into and when you expect to launch those products into the U.S. market?
We are very -- let's say, the ForMotion rebrand journey, it's very early days. We have just started in the Netherlands, which is a small part of our Patient Care business. We will introduce the ForMotion brand also in the U.S. later this year and in other smaller locations in Europe, so it's very, very early days. This is a change program that will stretch into next year and probably also into '26. And we'll, as I said earlier, take it step-by-step.
On your second question with regards to Fior & Gentz, again, going back to our earlier communication here, we did communicate, when we acquired the business, that 70% of sales was in Germany, and with the remaining sales being in a handful of European markets. As we write in our announcement today, we are preparing to introduce also Fior & Gentz into Australia and in the U.K. So we're still talking about a handful of markets. And going back to the logic for why we are good owners of this business is because individuals that have neuro or mobility challenges as a result of neurological complications are in most cases or in many cases referred to orthopedic and prosthetic clinics, and this is where we intend to leverage, obviously, our own clinical platform and relationships with O&P clinics in a global context. But it is still early days, but we are moving in line with our plans.
We will now take the next question. The next question comes from the line of Yiwei Zhou from SEB.
I have a few questions. I'll do one at a time. Firstly, just looking at your U.S. business and especially the Bracing & Supports segment, I remember, the first half, you were impacted by the cyber-attack on your major customer. And I understand that this has somehow eased here. But what can explain the weakness here in Q3? And what is your expectation for the remainder of the year?
Yes. Thanks for your question. Our Bracing business, we have a strong position in Bracing in a few of the biggest health care markets, U.S., the big health care markets in Europe. And in Bracing, we provide fundamental, let's say, solutions that are prevalent in each and every health care system and provide a fairly comprehensive portfolio of bracing.
Where we've seen the most positive growth dynamics, that is in and around our osteoarthritis bracing, where we provide bracing as an alternative to knee replacement surgery. And that segment continues to do well. Where we, however, have had more headwind that is in and around product categories, which are, you could say, simpler and where cost is a bigger topic and where there's also been some pressure in and around reimbursement or limited price increases. So it's a little bit of a mixed bag. We continue to see, as I said earlier, positive progress on the osteoarthritis front, while we have had more headwind in and around some of these more, you could say, commoditized categories that are exposed to more price pressure where we have seen some erosion. However, we continue to be optimistic on the Bracing business and our intention to grow in line with the market, sort of which is, yes, low single-digit growth rates.
And just one follow-up here. Is there any market you are looking into a possibility to divest the Bracing & Supports business or any market that has been sort of very long-term loss making and you could see that could lift your group margin, as you did in France?
No, we don't have any plans of that. And as you mentioned that we did go through -- our Bracing business has changed substantially since pre-COVID, where we divested a part of our business in France and a part of our business in U.S. And now we have a much stronger portfolio, and we have no intention of divesting any part of that business.
Okay. And when you mentioned the price pressure, could you elaborate a bit or confirm if that is sort of due to the increasing competition?
No, I wouldn't. I mean, this has always been a competitive field as such. And it's also important to remember that we are only in the reimbursed part of the bracing market. We don't compete in, let's say, the very low end sort of private pay market. We compete in the reimbursed market and it's where all -- let's say, those compete in that market are subject to regulatory requirements, quality requirements, and our customers are -- and it's a lot about being a complete provider and of a complete portfolio, where it's not as much where we -- if you compare to the Prosthetics & Neuro Orthotics segment, where we compete on different stations, here we're competing on ease of doing business having a full portfolio of high-quality bracing solutions.
But it is also a very regional business in the sense that reimbursement is very different country by country. And there are pockets, especially, as I mentioned earlier, in and around the more commoditized categories, which are more exposed to price pressure. While on the other hand, where we continue to see solid growth on the osteoarthritis side, where we have rather positive growth dynamics in all of our major markets.
Great. And next question is on Australia. I understand you have benefited a bit from the pent-up demand from this delayed reimbursement approval. Could you please indicate its effect on the Q3 growth, and maybe also comment on the Q4, if you can give any indication?
Yes. I mean, Australia is a relatively large share of our APAC business. We've talked about this in the first half of the year that there were some procedural complications in processing claims in the NDIS system in Australia. That seems to be gradually normalizing, you could say. And yes, there's a little bit of pent-up or demand that is being released here in quarter 3 and quarter 4, but it's not going to impact the bigger picture as such. But it's an important market for us, and it's nice to see that it's gradually or it's back to normal in Australia.
Okay. So it is a very small positive boost on your growth here in the quarter?
Yes, you could say it was a very small drag here in the first half of the year, and it's a slight boost here in the second half of the year, yes.
Okay. Great. And my next question on the gross margin here in Q3, it improved year-over-year, but actually lower than Q2. Is there like a seasonality here? And if you could also confirm that you have not been impacted by higher shipping costs?
We haven't been -- shipping cost hasn't been any major theme in our cost way. And yes, there can be a little bit seasonal fluctuation between quarter on the gross profit margin. But I think the big picture is that we are about 1 percentage point up if you look at the 9 months. And that is again a result of the actions we took earlier in the year around cost reduction in our manufacturing operations as well as mix and general productivity enhancement on also our Patient Care front.
Perfect. Last question on your CapEx to sales guidance. Could you remind us what is driving the higher investment here?
So in CapEx, we have been investing in facilities just to support our growth, mainly in Iceland and in the U.S., and the facility investments are now coming to an end. So we are back to more normalized level of CapEx.
Okay. Is it capacity or automation, because we also understand, on the other hand, that you have been cutting costs also in the production.
Some of it is. We've also been investing just to expand the facility for R&D activities, but yes, also some capacity expansion in the U.S. as well.
There are no further questions on the phone at this time. I would like to hand the call over for webcast questions.
Yes. I got a few additional questions from Nordea. So what are the next steps to leverage the U.S. coverage expansion? And what are the biggest speed bumps that we need to get past to start selling to the K2 patients?
Again, going back to the big picture, so what the, let's say, Medicare has concluded is that getting more patients using better solutions is, all else equal, going to drive down cost and increase the quality of life for these individuals. And if we see the data that we also went through here earlier, Medicare covers, we estimate, about 30% of the amputee population in the U.S. and about half of the claims processed are related to K2 patients. So yes, no matter how you look at it, it's going to grow the addressable market for prosthetic devices.
However, it's also important to remember that our business and the business of our customers is about servicing this existing population that is out there that every year needs to come back for maintenance or upgrade or renewal of their prosthetic device. So the easiest way to think about this is that you will -- let's say, that over time, the patient population that now has access to only lower level devices, if you will, will gradually get access to better devices. And there's a certain amount of fixed capacity in the system as well to see a fixed number of patients. So we estimate, from next year, that we'll start to see an impact from this, both on our, let's say, bionics business, but also remember that the system has now also decided to allow for access for higher-end feet as well.
So we expect our customers to gradually build up confidence and their processes around documentation such that they will start to get K2 patients on to better prosthetic devices. So we expect this to deliver, let's say, gradual growth. And what is also important to remember that Medicare only covers about 30% of the amputee population, but it's our assumption that private payers will adopt the line that Medicare has taken here, but we don't know the timing around that. So yes, I hope that answers your question. It's about our customers' ability, and that's also what we are working on. Now we are working heavily on sort of material and education material to help and support our customers on the reimbursement side going forward.
There's another one for Sven here from Nordea. So regarding APAC. So what is driving the soft sales in some of the APAC markets if you exclude Australia?
Yes. That is mainly -- another big market for us in the APAC region is China. And we have seen slow performance in China. China has always been a growth market for us. But with the economic softness in China, remember, this is a private pay market that has impacted demand here in 2024. And yes, we've seen an overall very slow year in China compared to prior years. With that said, we still remain optimistic on our potential in this market given low utilization of good mobility devices, and we'll continue to invest and grow our presence in China, but this has been an unusually slow year.
Then there's two questions here for Arna. First one is on CapEx. So these investments we have made recently, will it lift gross margin? And if so, how fast?
I don't expect this investment to lift the CapEx -- the gross port margin as such. It is more to support generally both our R&D activities as well as increased capacity we needed in operation.
Good. And then a final question here from Nordea on the net financials. So how should we think about net finances going forward?
Net financial is basically two components. This is the financial expenses, the interest rate, and then exchange differences. On the financial expenses, we can say that our interest rate cost is now currently around 40% -- sorry 4%, just to keep that clear. And we expect that you see basically that the interest rates are coming down in some announcement made yesterday about reduction in rates, and you can say that if you want to see a combination of U.S. dollars or U.S., we have now U.S. dollars approximately 25% of our loan or our borrowing portfolio and euro 75%. So you can start to estimate the cost.
I'll hand back to the moderator to take any final questions from the audience.
[Operator Instructions] There are no further questions at this time. I would like to hand back to management for any closing remarks.
Well, yes, thanks, everyone, for dialing in this morning. Please refer to our announcement with regards to our investor relations activities here over the next weeks and months. Otherwise, yes, I just wish you all a good day. Thank you very much.
This concludes today's conference call. Thank you for participating. You may now disconnect.